CASE REPORT

Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19: a case report and a review of the literature

Mark A. Colantonio¹, Divine C. Nwafor¹, Shruti Jaiswal⁵, Ashish K. Shrestha², Mahmoud Elkhooly³, Steven Rollins⁴, Sijin Wen⁴ and Shitiz Sриwastava¹,⁵,⁶*

Abstract

Background: Our case explored the spectrum of autoimmune and infectious neurological complications of Coronavirus Disease 2019. In addition, we also reviewed and discussed clinical features, neuroimaging, CSF findings, and outcomes in patients with COVID-19-associated Myelin Oligodendrocyte Glycoprotein Antibody Disorder (MOGAD) CNS inflammatory disorder.

Case presentation: Here we presented a case of post-Coronavirus Disease 2019 infection Myelin Oligodendrocyte Glycoprotein Antibody Disorder in a 41-year-old male who presented with gait instability, urinary retention, and confusion. Workup done in hospital showed transverse myelitis in cervical spine region and left optic neuritis. Laboratory findings showed Myelin Oligodendrocyte Glycoprotein-IgG antibodies were positive in serum (1:100), suggestive of post-COVID Myelin Oligodendrocyte Glycoprotein Antibody Disorder.

Conclusion: To our knowledge, this is the first comprehensive case report and the literature review that includes the clinical features, neuroimaging, CSF findings, and outcomes in COVID-19-associated Myelin Oligodendrocyte Glycoprotein Antibody Disorder.

Keywords: COVID-19, SARS-CoV-2, MOG, Optic neuritis, Myelitis, CSF, MRI in COVID-19

Introduction

The novel coronavirus has led to a myriad of complications, including central (CNS) and peripheral (PNS) nervous system dysfunction [1–5]. Coronavirus (SARS-CoV-2) neuropathogenesis is characterized by its hematogenous affinity for Angiotensin-converting enzyme 2 (ACE2) receptors localized to brain endothelial cells and retrograde spread via the glossopharyngeal, vagus, and olfactory nerves [6, 7]. Furthermore, the presence of ACE2 receptors in neurons and glial cells suggests a detrimental role of SARS-CoV-2 on CNS function [7]. Reports of Coronavirus Disease 2019 presenting as Acute Disseminated Encephalomyelitis (ADEM) [8], Myelin Oligodendrocyte Glycoprotein Antibody Disorder (MOGAD) [9], Miller Fisher syndrome [10], and Guillain–Barré syndrome [5] are critical examples of how SARS-CoV-2 may affect proper CNS function due to an aberrant immune response. MOG-IgG’s target MOG expressed in oligodendrocytes, which serve as a cellular receptor, adhesion molecule, or regulator of microtubule stability. The pathological effect of MOG-IgG relies on the ability of antibodies to enter the CNS. Thereafter,
MOG-IgG-associated neuroinflammation is mediated by T cells and complement-fixing antibodies, ultimately presenting as optic neuritis, transverse myelitis, and (ADEM) [11, 12].

We reported a Myelin Oligodendrocyte Glycoprotein Antibody Disorder case in a 41-year-old male who previously had mild Coronavirus Disease 2019 symptoms based on the ATS/IDSA guidelines [13]. The patient initially presented with transverse myelitis followed by left optic neuritis. Furthermore, we retrospectively discuss the various manifestations, relevant neuroimaging, and cerebrospinal fluid markers of Coronavirus infectious disease-2019 (nCov) associated with MOG-IgG reported to date.

**Case presentation**

A 41-year-old male tested positive for the Coronavirus Disease 2019 virus in early November of 2020. Initially, he recovered at home; however, he began to deteriorate, reporting whole-body shivering, confusion, paresthesia, gait instability, and urinary retention 16 days post-COVID diagnosis. His medical comorbidities included hypertension, ethanol, and methamphetamine substance abuse. On examination, the patient appeared diaphoretic, uncomfortable, and was slow to respond to questioning. Initial workup revealed elevated BUN/Creatinine ratio of 24 (range 10.1–20.1), prothrombin time 14.2 secs (range 9.1–13.9), INR 1.23 secs (range 0.80–1.20), venous pH 7.44 (range 7.31–7.41), lactate 1.4 mmol/L (range 0.0–1.3), venous bicarbonate 27 mmol/L (range 22–26), WBC count 18.3 × 10³/µL (range 3.7–11.0 × 10³), CRP inflammatory maker 9 mg/L (range >8), neutrophil 14.15 × 10³ (range 1.50–7.70 × 10³) and PO₂ 30 mm/Hg (range 35–50), and creatine kinase 23 U/L (range 45–225).

Upon admission, the patient underwent magnetic resonance imaging of the spine and brain with and without (w/wo) contrast. MRI of the spine revealed abnormal T2 hyperintensity from C2–C4 without post-contrast enhancement. These results were suggestive of longitudinally extensive transverse myelitis and post-infectious transverse myelitis (Fig. 1). Subsequent lumbar puncture revealed polymorphonuclear leukocytes with an absence of organisms and neutrophilic predominance. CSF revealed 45/µL nucleated cells (range 0–5), 90% lymphocytic predominance, 116 mg/dL protein (range 15–50), 37 mg/dL glucose (range 50–80), 0 oligoclonal bands, and IgG index 0.48. CSF and serum NMO Antibody were negative, and an MOG test was not performed. For possible meningoencephalitis, the patient was treated with IV ceftriaxone, vancomycin, ampicillin,
and acyclovir. On day 6 of admission, a repeat brain MRI suggested a new T2-FLAIR lesion of the left corona radiata and right parietal subcortical white matter. Antibiotics were discontinued as CSF was negative for viral PCR; however, the patient remained confused and lethargic. IV Solumedrol 1 g/day for 5 days was administered, and possible post-COVID CNS inflammatory disorder was suspected.

On day 7 of admission, a follow-up lumbar puncture revealed several polymorphonuclear leukocytes with an absence of organisms and a lymphocytic predominance. CSF analysis yielded 23/µL nucleated cells, protein 62 mg/dL and glucose 44 mg/dL. The patient’s mental status improved significantly with the administration of Solumedrol. The diagnosis of post-infectious COVID-19 encephalomyelitis was made, and the patient was discharged 22 days after admission and instructed to follow-up with a neurologist in the next 3 months. At this time, the patient was stable without deficits.

Six months later, the patient returned with complaints of a mild left-sided headache and left-sided retro-orbital pain with visual blurriness occurring over 1 week. The patient was initially seen in the ED, and a workup for possible demyelinating lesions was recommended. Examination of visual acuity in both eyes showed impaired left visual acuity (20/70), right 20/25, and left afferent pupillary defect (APD). Intraocular pressure and extraocular muscles (EOM) were within normal limits and intact. Ophthalmology recommended the patient for orbital MRI with/without contrast for evaluation of potential optic nerve lesions. Brain and orbital MRI w/wo contrast revealed pre-chiasmatic (intracanicular) enhancement of the left optic nerve, suggestive of optic neuritis (Fig. 1). The patient’s concern was encephalopathy, optic neuritis, spinal, and brain lesions raised concern for neurological inflammatory post-COVID vaccination sequela. Hence, CNS inflammatory marker MOG-IgG antibody levels were sent out and tested commercially at the Mayo Clinic via live-cell fluorescent-activated cell sorting assay. MOG-IgG antibodies were positive in serum (1:100), suggestive of post-COVID MOGAD syndrome. Neurology was then consulted for further workup based on the patient’s history of prior CNS lesions and current complaint of left-sided headache and left eye pain. Per neurology recommendations, a repeat MRI of the cervical and thoracic spine w/wo contrast was ordered to rule out multiple sclerosis (MS). MRI imaging was unremarkable and showed no new or enhancing lesion, with an absence of demyelinating lesions in the thoracic spinal cord. Brain MRI revealed decreased conspicuity of previously visualized white matter lesions. Although the patient was admitted, he was started on IV solumedrol (1 g/day for 3 days) and prescribed oral prednisone 1250 mg daily for an additional 2 days to be taken at home following discharge. Although admitted, the patient was scheduled to receive five cycles of PLEX therapy; however, on cycle 3/5, the patient became septic, and PLEX was held in the setting of bacteremia and thrombophlebitis due to a port infection. The remaining PLEX cycles were deferred due to sepsis. The patient stated he had significant improvement of his optic neuritis and visual acuity after receiving 3/5 PLEX cycles and concurrent solumedrol. Following resolution of the patient’s acute bacteremia, he was instructed to return in 1 month for a follow-up visit.

At the patient’s follow-up visit with neurology, the patient reported that his vision had significantly improved, and he is currently stable since his last admission. He no longer has pain and stated his visual acuity had returned near to baseline. Per neurology recommendations and infectious disease clearance, the patient will continue monthly IVIG therapy for suspected post-COVID MOGAD optic neuritis.

**Discussion**

Myelin Oligodendrocyte Glycoprotein Antibody Disorder is an inflammatory demyelinating condition of the central nervous system characterized by a monophasic or relapsing neurological dysfunction (optic neuritis, myelitis, and brainstem encephalitis). The findings specific to MOGAD include seropositive MOG-IgG antibodies, and frequently, CNS demyelination via MRI. These findings are MOGAD specific and do not meet diagnostic criteria for MS or other known neuroinflammatory conditions [11, 12, 14].

According to the literature, almost 50% of the patients diagnosed with Myelin Oligodendrocyte Glycoprotein Antibody Disorder present with myalgia, fever, respiratory symptoms, and gastrointestinal symptoms [15, 16]. The post-infectious state of MOGAD may be due to herpes simplex virus, cytomegalovirus, Borrelia, and Epstein–Barr virus infections [16–19]. Several cytokines and inflammatory markers have been implicated to play a role in the post-infectious state and development of MOG-IgG antibodies, including CRP, α-dimer, IL-6, 7, 19, GCSF, IP 10, MCP1, MIP1A and TNF alpha [20]. However, the mechanism contributing to the MOG-IgG antibody is unclear [11].

Interestingly, the recent data suggest a role for Coronavirus Disease 2019 in Myelin Oligodendrocyte Glycoprotein Antibody Disorder relapse [21]. COVID-19-associated MOGAD relapse is likely from the host reaching a threshold, leading to production of MOG-IgG1B-cell [22–24]. More importantly, these findings demonstrate that the SARS-CoV-2 virus may impact disease exacerbation in other relapsing CNS inflammatory disorders [21].
Among initial and relapsing presentations of Myelin Oligodendrocyte Glycoprotein Antibody Disorder, optic neuritis is the most common in adults, ranging between 54 and 60%. A unilateral lesion is seen in 22–40% and bilateral lesion seen in 22–42% [15, 16, 25]. Other clinical manifestations include myelitis, seen in 22–36% of cases, and symptoms of brainstem and encephalopathy syndrome. However, symptomatic presentation of MOGAD appears to be age dependent, as a child will most commonly present with ADEM [15, 26].

Myelin Oligodendrocyte Glycoprotein Antibody Disorder can be further differentiated from other neurological inflammatory conditions based on cerebrospinal fluid findings. MOGAD patients have been shown to yield pleocytosis in 33–66%, and Cobo-Calvo and his colleagues demonstrate it to be more common among children [27]. CSF protein elevation is only found in 27–37% and 11–22% cases can have presence of oligoclonal bands. Differences in CSF composition were further explored in our literature review. Fisher’s exact test was used to assess alterations in CSF composition, including protein, cell count, lymphocytes in post-COVID MOGAD patients. We showed no significant differences in protein, cell count, and lymphocytes were found by age (50+ versus 50−), gender, COVID-19 severity, and fatality, respectively (refer to Table 1).

Shared similarities were noted in our case report and published literature. For instance, the patient described in this report initially presented with paresthesia and gait disturbances that improved with Solumedrol. 6 months later, the patient presented with deteriorating symptoms and complaints of optic neuritis. This progression is consistent with MOGAD’s relapsing symptomatic clinical presentation [15, 26]. Furthermore, MRI imaging studies in our patient were consistent with post-infectious transverse myelitis and optic neuritis. Likewise, MOG-IgG antibody titers were elevated (1:100). Taken together, the clinical presentation, imaging studies, and serological analysis seen in our patient strongly supported findings consistent with typical MOGAD presentation [11, 12, 14]. Literature also suggests pleocytosis is a unique and consistent finding in the CSF, as shown in our patient presentation [28].

In addition to our described case report, we conducted a literature review to examine findings from published Myelin Oligodendrocyte Glycoprotein Antibody Disorder data. Table 2 describes MOGAD cases that showed a correlation between COVID-19 and MOGAD. After a comprehensive literature review, 12 cases were identified, with 11 cases fulfilling the diagnostic criteria for MOGAD based on MOG encephalomyelitis: international recommendations on diagnosis and antibody testing [14]. Regarding MOG-IgG Ab, all 11 cases of MOGAD were found to be MOG-IgG Ab serum positive, while only a single case by Khan and his colleagues tested CSF for MOG-IgG Ab and was found to be negative [28] (refer to Table 2). Symptomatic presentation of MOGAD was consistent. Among the 12 reviewed cases, eight presented with symptoms of optic neuritis, as reported by Sawalha and his colleagues, Zhou and his colleagues, Khan and his colleagues, Sardar and his colleagues, Kogure and his colleagues, and de Ruijter and

| Table 1 | CSF findings in patients with post-COVID MOGAD disease |
|---------|--------------------------------------------------------|
| Variables | CSF protein | CSF cell count | CSF lymphocyte % |
|          | Low (≤ 45) | High (> 45) | N (%) | p | No (≤ 5) | Yes (> 5) | N (%) | p | ≤ 50% | > 50% | N (%) | p |
| Age      |            |             |       |   |         |          |       |   |       |       |       |   |
| 50+      | 0 (0)      | 1 (100)     | 1 (14.3)| 0.4| 0 (0)   | 1 (100)  | 1 (20) | 1 | No CSF | No CSF | NA  |
| < 50     | 4 (67)     | 2 (33)      | 6 (85.7)| 2 (50)| 2 (50) | 4 (80)   | 3 (75) | 1 (25) | 4 (100) |         |   |
| Gender   | Female     | 1 (50)      | 1 (100) | 1 | 1 (100) | 0 (0)    | 1 (20) | 0.4| 1 (100) | 0 (0) | 1 (25) | 1 |
| Male     | 3 (60)     | 2 (40)      | 5 (71.4)| 1 (25)| 3 (75) | 4 (80)   | 2 (67) | 1 (33) | 3 (75) |         |   |
| COVID-19 severity  | | | | | | | | | | | | |
| Non-severe | 3 (50)       | 3 (50)     | 6 (85.7)| 1 | 1 (25) | 3 (75)   | 4 (80) | 0.4| 2 (67) | 1 (33) | 3 (75) | 1 |
| Severe   | 1 (100)    | 0 (0)       | 1 (14.3)| 1 (100) | 0 (0) | 1 (20)   | 1 (100) | 0 (0) | 1 (25) |         |   |
| Fatality | Non-fatal  | 4 (57.1)    | 3 (42.9)| 7 (100) | NA | 2 (40)   | 3 (60) | 5 (100) | NA | 3 (75) | 1 (25) | 4 (100) | NA |
| Fatal    | 0 (0)      | 0 (0)       | 0 (0)  | 0 | 0 (0)   | 0 (0)    | 0 (0) | 0 |       |       |       |   |

CSF cerebrospinal fluid, NA not applicable
p values were calculated from Fisher’s exact test. All observations were non-fatality and thus a Fisher’s exact test was not available between fatality and the outcomes of interest

 Severity based on the IDSA/ATS guidelines
| Author/country         | Patient age/gender | Time duration from COVID-19 to neurological symptom onset | Time duration from COVID-19 to MOG AB positive | Co-morbidity | Neurological presentation | CSF findings | Serum/CSF AQP4, and ANTI-MOG Ab | MRI findings | Diagnosis | Management | Outcomes | Severity based on IDSA/ATS* |
|-----------------------|--------------------|----------------------------------------------------------|-----------------------------------------------|--------------|---------------------------|------------|-------------------------------|-------------|-----------|------------|----------|---------------------------|
| Sawalha et al./USA    | 44/M               | 2 weeks                                                  | 3 weeks                                       | None         | Bilateral eye pain and vision loss | CSF WBC 3/ mm³, protein 50 mg/dL, glucose 88 mg/dL, OCB negative | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | Brain MRI showed enhancement in the right more than the left optic nerve suggestive of optic neuritis although no other abnormalities were noted in brain, cervical, or thoracic spine | MOG antibody-associated optic neuritis | IVMP * 5 days tapering Prednisolone | Not fatal | Not severe |
| Zhou et al./USA       | 26/M               | < 1 week                                                 | 1 day                                         | None         | Sequential vision loss first affecting the left eye, then the right eye 3 days later | CSF WBC 55/ mm³, protein 31 mg/dL, glucose 57 mg/dL, OCB mirror | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI of the brain and orbits uniform enhancement and thickening of both optic nerves with non-specific focal lesion in left occipital area. MRI spine focal patchy lesion in C and T spine with enhancement | MOG associated optic neuritis and myelitis | IVMP * 5 days tapering Prednisolone | Not fatal | Not severe |
| Author/country | Patient age/gender | Time duration from COVID-19 to neurological symptom onset | Time duration from COVID-19 to MOG AB positive | Co-morbidity | Neurological presentation | CSF findings | Serum/CSF AQP4, and ANTI-MOG Ab | MRI findings | Diagnosis | Management | Outcomes | Severity based on IDSA/ATS* |
|----------------|-------------------|----------------------------------------------------------|-----------------------------------------------|--------------|--------------------------|-------------|---------------------------|-------------|----------|-----------|----------|--------------------------|
| Khan et al./India | 11/M | 1 week | 2 weeks | None | Rapidly progressive loss of vision | CSF WBC 55/mm³, protein normal, glucose normal, OCB negative | Serum AQP4 negative, CSF AQP4 NA, Serum MOG Ab positive, CSF MOG Ab negative | MRI orbit bilateral asymmetric optic neuritis, with enhancement of the optic nerve sheath in the right orbit | MOG associated optic neuritis | IVMP * 5 days | Tapering Prednisolone | Not fatal | Not severe |
| Sardar et al./Qatar | 38/F | 2 weeks | NA | Diabetes, Migraine, Obesity, Obstructive sleep apnea, Gastritis | Headache, Diminution of vision, With painful eye movement | CSF WBC normal, protein normal, glucose normal, OCB-NA | Serum AQP4 NA, CSF AQP4 NA, Serum MOG Ab NA, CSF MOG Ab NA | MRI orbit T2 signal bilateral optic nerve and enhancement | Seronegative NMOSD and IIH | IVMP for 5 d, MG*5 days PLEX Acetazolamide | Not fatal | Not severe |
| Zorić et al./Serbia | 63/M | 4 weeks | 11 weeks | Diabetes | Headache, Left eye visual loss | Headache, Left eye visual loss | Serum AQP4 positive, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI brain microangiopathic and a neuroglial cyst on the right temporal side, and normal appearing orbits and optic nerves | MOG associated optic neuritis | IVMP *5 days Tapering Prednisolone | Not fatal | Not severe |
| Author/country  | Patient age/gender | Time duration from COVID-19 to neurological symptom onset | Time duration from COVID-19 to MOG AB positive | Co-morbidity | Neurological presentation | CSF findings | Serum/CSF AQP4, and ANTI-MOG Ab | MRI findings | Diagnosis | Management | Outcomes | Severity based on IDSA/ATS⁹ |
|----------------|--------------------|----------------------------------------------------------|-----------------------------------------------|--------------|--------------------------|-------------|----------------------------|-------------|----------|-----------|---------|--------------------------|
| Pinto et al./UK| 44/F               | 1 week                                                   | 30 days                                      | None         | Mild expressive and receptive dysphasia, visual and sensory inattention | CSF WBC 13/mm³, protein 507 mg/dL, glucose 52 mg/dL, OCB negative | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI brain hyperintensity within bilateral periventricular area extending left temporal and occipital horns and into the subcortical deep white matter bilateral. There was perivascular enhancement within the lesions, and MRA was normal. MRI the spine normal. MRI orbit not reported. | CNS inflammatory vasculopathy with anti-MOG | IVMP * 5 days Tapering Prednisolone PLEX * 5 Sessions | Not fatal | Not severe |
Table 2 (continued)

| Author/country       | Patient age/gender | Time duration from COVID-19 to neurological symptom onset | Time duration from COVID-19 to MOG AB positive | Co-morbidity | Neurological presentation | CSF findings | Serum/CSF AQP4, and ANTI-MOG Ab | MRI findings | Diagnosis | Management | Outcomes | Severity based on IDSA/ATSa |
|----------------------|--------------------|----------------------------------------------------------|------------------------------------------------|--------------|---------------------------|--------------|---------------------------------|--------------|-----------|------------|----------|---------------------------|
| Vraka et al./UK      | 13m/F              | 1 week                                                   | 4 days                                        | None         | Altered consciousness, seizures | CSF WBC 10/mm³, protein 31 mg/dL, glucose 84 mg/dL, OCB negative | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI brain hyperintensity in the splenium of the corpus callosum with associated diffusion restriction and high signal in the thalami and pons | MRI spine normal | MOG antibody myelitis | IVMP, acyclovir, levetiracetam | Not fatal | Severe |
| Kogure et al./Japan  | 47/M               | NA                                                      | 2 days                                        | Recurrent Paranasal sinusitis, Adrenal resection | Left eye pain, Visual loss | CSF WBC normal, protein normal, glucose normal, OCB-NA | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab negative | MRI orbit revealed the bilateral uniform enhancement along with optic nerve sheaths | MOG associated optic neuritis | IVMP *3 days, Tapering Prednisolone | Not fatal | Not severe |
| Jumah et al./USA     | 61/M               | 1 week                                                   | 1 day                                         | None         | Retention sensory Level at T7, paraplegia | CSF WBC 279/mm³, protein 106 mg/dL, glucose NA, OCB negative | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI showed T2 hyper intense lesions of variable length in the mid-thoracic spinal cord, while brain MRI was unremarkable | MOG antibody myelitis/HHV myelitis | IVMP, PLEX, ganciclovir | Not fatal | Not severe |
Table 2 (continued)

| Author/country          | Patient age/gender | Time duration from COVID-19 to neurological symptom onset | Time duration from COVID-19 to MOG AB positive | Co-morbidity | Neurological presentation | CSF findings | Serum/CSF AQP4, and ANTI-MOG Ab | MRI findings | Diagnosis | Management | Outcomes | Severity based on IDSA/ATSa |
|------------------------|--------------------|----------------------------------------------------------|-----------------------------------------------|--------------|---------------------------|--------------|-------------------------------|--------------|-----------|------------|----------|------------------------|
| de Ruijter et al./Netherland | 15/M              | > 1 week                                                  | NA                                            | None         | Subacute bilateral visual loss over the course of 7 day | CSF WBC normal, protein normal, glucose normalb, OCB-NA | Serum AQP4 negative, CSF AQP4 NA, Serum MOG Ab positive, CSF MOG Ab NA | MRI orbit revealed a bilateral edematous optic nerve lesion | MOG associated optic neuritis | IVMP * 3 days | Not fatal | Not severe |
| Woodhall et al./UK     | 39/F              | < 1 week                                                  | 6 days                                        | MOGAD        | Painful progressive right visual loss consistent with optic neuritis | CSF NA          | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI progression of right optic nerve atrophy and subtle T2 signal hyperintensity | MOG associated relapse optic neuritis | IVMP * 5 days Mycophenolate, PLEX * 5 Sessions | Not fatal | Not severe |
| Peters et al./USA      | 23/M              | 2 weeks                                                  | 2 weeks                                       | Childhood non-febrile seizures | Generalized tonic Clonic seizure, slowing Fever | CSF WBC 57/mm³, protein 40 mg/dl, glucose-60 mg/dlb, OCB negative | Serum AQP4 negative, CSF AQP4 NA, serum MOG Ab positive, CSF MOG Ab NA | MRI brain diffuse left-hemispheric cortical hyperintensity, most pronounced in the left occipital and posterior temporal lobe with leptomeningeal enhancement Spine MRI not reported | MOG-associated encephalitis | IVMP * 5 days | Not fatal | Not severe |

MOGAD myelin oligodendrocytes glycoprotein antibody disease, AQP4 aquaporin antibody, IVIG intravenous immunoglobulin, PLEX plasmapheresis, IVMP intravenous methylprednisolone, MRI magnetic resonance imaging, CSF cerebrospinal fluid, OCB oligoclonal bands

a Severity based on the Infectious Diseases Society of America IDSA and American Thoracic Society ATS guidelines

b Serum glucose not reported or available
his colleagues, most commonly involving the pre-chiasmal optic nerve [9, 28–31]. Other patient presentations included altered mental status and seizure disorder by Vraka and his colleagues, and Peters and his colleagues, whereas Jumah and his colleagues reported a case of paraplegia [26, 32, 33].

In all cases, Myelin Oligodendrocyte Glycoprotein Antibody Disorder-IgG antibody levels were measured to diagnose Myelin Oligodendrocyte Glycoprotein Antibody Disorder related to Coronavirus Disease 2019 sequel. In 4 cases, MOG antibody tested positive between 2 and 4 weeks [28, 30, 32, 34] whereas Žorić and his colleagues reported a case where MOG-IgG was positive more than 4 weeks after SARS-CoV-2 RT-PCR positive test [35]. The remaining cases of MOG-IgG positivity were reported within 1 week of the initial COVID-19 positive test (refer to Table 2). Based on this data, MOGAD should not be dismissed solely of the amount of time passed between the initial COVID-19 positive test and subsequent MOG-IgG testing.

Cerebrospinal fluid was also analyzed to distinguish Myelin Oligodendrocyte Glycoprotein Antibody Disorder from other neuroinflammatory diseases further. More than half of the CSF in the studied cases (6 out of 10) revealed pleocytosis. In contrast, only 3 cases by Sawalha and his colleagues, Pinto and his colleagues, and Jumah and his colleagues reported high protein levels in the CSF [30, 33, 34]. Oligoclonal bands in CSF were assessed in 8 cases; however, no cases had unique isolated bands in CSF (refer to Table 2).

Upon further analysis of the cases, two-third of cases (7/12) showed T2 hyperintensity and post-contrast enhancement in the prechiasmal optic nerves with sparing of chiasma and optic tract. Woodhall and his colleagues was the only case to report unilateral optic nerve involvement [21]. In addition, Zhou and his colleagues reported a case of MOGAD with findings of optic neuritis and myelitis. Subsequent MRI showed non-enhancing, non-specific periventricular T2 hyperintensity adjacent to the occipital horn of the right lateral ventricle with patchy T2 hyperintensities in the lower cervical and upper thoracic spinal cord. Mild central thickening and gadolinium enhancement were also observed [9]. However, Jumah and his colleagues reported a case of MOGAD with subsequent spinal MRI imaging revealing the spine revealing non-enhancing T2 hyperintense lesions of variable length in the mid-thoracic spinal cord [33]. Peters and his colleagues reported encephalitis with MRI finding of T2 hyperintensity in left occipital and posterior temporal lobe with leptomeningeal enhancement [32]. Moreover, Vraka and his colleagues reported MRI findings of bilateral widespread white matter high-signal abnormalities, including the splenium of the corpus callosum with associated diffusion restriction and high signal in the thalami and pons in a diagnosed MOGAD 13-month-old female [26] (refer Table 2).

The studied cases used similar treatment for Myelin Oligodendrocyte Glycoprotein Antibody Disorder. All cases recovered after initiation of intravenous methylprednisolone. Only 4 cases by Sardar and his colleagues, Pinto and his colleagues, Jumah and his colleagues, and Woodhall and his colleagues were treated with plasma therapy due to the slow and partial improvement in symptoms [21, 29, 33, 34]. The above therapies proved to yield a favorable outcome with the treatment of MOG antibody disorder.

One limitation of this review study was the small sample size used. A future study should be considered with a larger sample size when there is a greater prevalence of concurrent COVID-19 related MOGAD. This will help further explore similarities and differences among patient symptom presentations, imaging similarities, CSF analysis, and treatment outcomes.

**Conclusion**

Our case explored the spectrum of autoimmune and infectious neurological complications of Coronavirus Disease 2019. In addition, we also reviewed and discussed clinical features, neuroimaging, CSF findings, and outcomes in patients with COVID-19-associated MOGAD CNS inflammatory disorder. Our cases provided insight regarding the need to test specific demyelinating antibodies, such as MOG-IgG in the setting of a suspicious clinical picture, such as longitudinally extensive myelitis or severe optic neuritis, especially in the setting of a concurrent or previous COVID-19 infection. Future research should focus on early diagnosis of MOGAD and testing modalities, such as MRI imaging, serum, and CSF analyses. In light of this, we believe this review will be an essential aid to future studies on CNS inflammatory disorders, such as MOGAD in relation to COVID-19 and provide helpful information for researchers and registries to collect future data on MOGAD and COVID-19.

**Abbreviations**

COVID-19: Coronavirus infectious disease-2019; nCov: Novel Coronavirus; SARS-CoV-2: Severe Acute Respiratory Distress Syndrome coronavirus 2; CSF: Cerebrospinal fluid; CNS: Central nervous system; PNS: Peripheral nervous system; ACE2: Angiotensin-converting enzyme 2; RT-PCR: Reverse transcription polymerase chain reaction; IDSA/ATS: Infectious Diseases Society of America/American Thoracic Society; AHNE: Acute hemorrhagic necrotizing encephalitis; AHLE: Acute hemorrhagic leukoencephalitis; ADEM: Acute Disseminated Encephalomyelitis; MRI: Magnetic resonance imaging; CLOCC: Cytotoxic lesion of the Corpus Callosum; MOG: Myelin Oligodendrocyte Glycoprotein; MERS: Mild encephalopathy reversible splenium lesion; MOGAD: Myelin Oligodendrocyte Glycoprotein Antibody Disorder; GBS: Guillain–Barre syndrome; WHO: World Health Organization; IVIG: Intravenous immunoglobulin; IVMP: Intravenous methylprednisolone; PLEX: Plasma exchange/plasmapheresis.
Acknowledgements

West Virginia Clinical and Translational Science Institute, Morgantown, WV; SW and SS supported in part by WVCTSI via US National Institute of General Medical Sciences of National Institute of Health under award under S15GM104942-05

Author contributions

Conceptualization: SS. Drafting manuscript: DN, AC, AS, ME, SJ, SS. Data abstraction and data analysis: SR, SW. Final edit: SS. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

Data was extracted from the articles published in PUBMED, Google Scholar, Scopus. This will be provided on request.

Declarations

Ethics approval and consent to participate

This is under compliance with institutional review board guidelines and approval IRB protocol number 2004958561 from WWU (date 4-6-2020).

Informed consent

Informed written consent from the patient was obtained.

Consent for publication

Available and IRB approved; and written consent obtained from patient.

Competing interests

All authors declared no potential conflicts of interest.

Author details

1School of Medicine, West Virginia University, Morgantown, WV, USA. 2Kathmandu Medical College Teaching Hospital, Kathmandu, Nepal. 3Department of Neurophysiatry, Minia University, Minia, Egypt. 4Department of Biostatistics, West Virginia University, Morgantown, WV, USA. 5West Virginia Clinical and Translational Science Institute, Morgantown, WV, USA. 6Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, One Medical Center Dr, Suite 1310, Morgantown, WV 26506-9180, USA.

Received: 9 February 2022   Accepted: 17 May 2022

Published online: 31 May 2022

References

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10232):497–506.
2. Munhoz RP, Pedroso JL, Nascimento FA, Almeida SMD, Barsottini OGP, Cardoso FEC, et al. Neurological complications in patients with SARS-CoV-2 infection: a systematic review. Arq Neuropsiquiatr. 2020;78(S):293–300.
3. Chowdhry A, Subedi R, Tandon M, Wen S, Patel J, Kataria S, et al. Relevance and clinical significance of magnetic resonance imaging of neurological manifestations in COVID-19: a systematic review of case reports and case series. Brain Sci. 2020,10(12):1017.
4. Berger JR. COVID-19 and the nervous system. J Neurol. 2020;262(2):143–8.
5. Sritiwasava S, Kataria S, Tandon M, Patel J, Patel R, Jowkar A, et al. Guillain-Barré syndrome and its variants as a manifestation of COVID-19: a systematic review of case report and case series. J Neurol Sci. 2020;420: 117263.
6. Li Z, Liu T, Yang N, Han D, Mi X, Li Y, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain. Front Med. 2020;14(S):S33–41.
7. Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host–virus interaction, and proposed neurotropic mechanisms. ACS Chem Neurosci. 2020,11(7):995–8.
8. Novi G, Rossi T, Pedemonte E, Saitta L, Rotta I, Roccatagliata L, et al. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurolo Neuromimmunol Neuroinflamm. 2020. https://doi.org/10.1212/ NNX.0000000000000797.
9. Zhou S, Jones-Lopez EC, Soneji DJ, Azevedo CJ, Patel VR. Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis and myelitis in COVID-19. J Neuro-Ophthalmol. 2020. https://doi.org/10.1097/WNO.0000000000001049.
10. Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, San Pedro-Murillo E, Bermejo-Guerrero L, Gordo-Mañas R, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95(5):e601–5.
11. Wynford-Thomas R, Jacob A, Tommassini V. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280–6.
12. Lana-Peixoto MA, Talmi N. Neuromyelitis optica spectrum disorder and anti-MOG syndromes. Biomarkes. 2019,7(2):42.
13. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Cotrothers K, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and infectious diseases society of America. Am J Respir Crit Care Med. 2020,199(7):e45–67.
14. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neurolinflamm. 2018,15(1):134.
15. Ramanathan S, Mohammad S, Tantis E, Nguyen TK, Merheb V, Fung VSC, et al. Clinical course, therapeutic responses and outcomes in relapsing-MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry. 2018,89(2):127–37.
16. Mariotti S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multi-center study. J Neurol. 2017,264(12):2420–30.
17. Nakamura M, Iwasaki Y, Takahashi T, Kaneko K, Nakashima I, Kunieda T, et al. A case of MOG antibody-positive bilateral optic neuritis and meningogangliositis following a genital herpes simplex virus infection. Mult Scler Relat Disord. 2017,1:148–50.
18. Vieira JP, Sequeira J, Brito MJ. Postinfectious anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis and myelitis. J Child Neurol. 2017,32(12):996–9.
19. Nakamura Y, Nakajima H, Tani H, Hosokawa T, Ishida S, Kimura F, et al. Anti-MOG antibody-positive ADEM following infectious mononucleosis due to a primary EBV infection: a case report. BMC Neurol. 2017,17(1):76.
20. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020,395(10229):1033–4.
21. Woodhall M, Mitchell JW, Gibbons E, Healy S, Waters P, Huda S. Case Report: myelin oligodendrocyte glycoprotein antibody-associated relapse with COVID-19. Front Neurol. 2020,11: 59831.
22. Piddilderen SJ, Lassmann H, Zimpich F, Morgan BP, Lintoning C. The demyellating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 1993,143(2):555–64.
23. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest. 2006,116(9):2393–402.
24. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013,9(8):465–61.
25. Cobo-Calvo A, Ruiz A, Maillart E, Audoin B, Zephir H, Boure B, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology. 2020,90(11):W000001049.
26. Woodhall M, Mitchell JW, Gibbons E, Healy S, Waters P, Huda S. Case Report: myelin oligodendrocyte glycoprotein antibody-associated relapse with COVID-19. Front Neurol. 2020,11: 59831.
27. Piddilderen SJ, Lassmann H, Zimpich F, Morgan BP, Lintoning C. The demyellating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 1993,143(2):555–64.
28. Bettelli E, Baeten D, Jäger A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J Clin Invest. 2006,116(9):2393–402.
29. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013,9(8):465–61.
28. Khan A, Panwala H, Ramadoss D, Khubchandani R. Myelin oligodendrocyte glycoprotein (MOG) antibody disease in a 11 year old with COVID-19 infection. Indian J Pediatr. 2021;88:488–9.

29. Sardar S, Safan A, Okar L, Sadik N, Adeli G. The diagnostic dilemma of bilateral optic neuritis and idiopathic intracranial hypertension coexistence in a patient with recent COVID-19 infection. Clin Case Rep. 2021;9: e04347.

30. Sawalha K, Adeodokun S, Kamoga GR. COVID-19-induced acute bilateral optic neuritis. J Investig Med High Impact Case Rep. 2020;8:2324709620976018.

31. de Ruijter NS, Kramer G, Gons RAR, Hengstman GJD. Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report. Mult Scler Relat Disord. 2020;46: 102474.

32. Peters J, Alhasan S, Vogels CB, Grubaugh ND, Farhadian S, Longbrake EE. MOG-associated encephalitis following SARS-COV-2 infection. Mult Scler Relat Disord. 2021;50: 102857.

33. Jumah M, Rahman F, Figgie M, Prasad A, Zampino A, Fadhil A, et al. COVID-19, HHV6 and MOG antibody: a perfect storm. J Neuroimmunol. 2021;353: 577521.

34. Pinto AA, Carroll LS, Nar V, Varatharaj A, Galea I. CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. Neurol Neuroimmunol Neuroinflamm. 2020. https://doi.org/10.1212/NXI.00000000000000813.

35. Žorić L, Rajović-Atić I, Colak E, Mirić D, Kišić B. Optic neuritis in a patient with seropositive myelin oligodendrocyte glycoprotein antibody during the post-COVID-19 period. Int Med Case Rep J. 2021;14:349–55.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com